# Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

> **NCT06118151** · PHASE1 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 388 (actual)

## Conditions studied

- Influenza
- Influenza Immunization

## Interventions

- **BIOLOGICAL:** Influenza Hemagglutinin mRNA vaccine
- **BIOLOGICAL:** Quadrivalent Recombinant Influenza Vaccine

## Key facts

- **NCT ID:** NCT06118151
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-11
- **Primary completion:** 2023-02-17
- **Final completion:** 2023-02-17
- **Target enrollment:** 388 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06118151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06118151, "Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06118151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*